文献速递临床试验与 GCP流行病学与生物统计

极早产儿生后7-14天启动氢化可的松对死亡或支气管肺发育不良的影响:随机临床试验

Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

该双盲安慰剂对照随机试验在荷兰和比利时19个NICU纳入胎龄<30周和/或出生体重<1250 g、生后7-14天仍依赖机械通气的极早产儿,比较22天氢化可的松方案(累积剂量72.5 mg/kg)与安慰剂。主要复合结局死亡或BPD在36周校正胎龄时两组无显著差异(70.7% vs 73.7%,校正OR 0.87,95%CI 0.54-1.38,P=0.54)。结论不支持该指征使用氢化可的松。

要点

  • 生后7-14天启动氢化可的松未降低36周校正胎龄死亡或BPD复合结局。
  • 氢化可的松组死亡发生率较低(15.5% vs 23.7%),但BPD无显著差异。
  • 需胰岛素治疗的高血糖在氢化可的松组更常见(18.2% vs 7.9%)。

核心结论

  • 在依赖机械通气的极早产儿中,生后7-14天启动氢化可的松与安慰剂相比未改善36周校正胎龄死亡或BPD复合结局,不支持该指征使用。

研究设计与样本

  • 双盲、安慰剂对照随机试验,在荷兰和比利时19个新生儿重症监护病房开展,2011年11月15日至2016年12月23日纳入胎龄<30周和/或出生体重<1250 g、生后7-14天仍依赖机械通气的极早产儿,随访至出院(2017年12月12日结束)。
  • 共372例随机(氢化可的松组n=182,安慰剂组n=190),371例完成试验,平均胎龄26周,55%为男性。
  • 干预为22天疗程全身氢化可的松(累积剂量72.5 mg/kg)或安慰剂。

主要发现

  • 主要复合结局死亡或BPD在氢化可的松组181例中128例(70.7%)、安慰剂组190例中140例(73.7%)发生(校正风险差-3.6%,95%CI -12.7%至5.4%;校正OR 0.87,95%CI 0.54-1.38;P=0.54)。
  • 需胰岛素治疗的高血糖是唯一在氢化可的松组报告更多的 adverse effect(18.2% vs 7.9%)。

临床怎么用

  • 对于生后7-14天仍依赖机械通气的极早产儿,不应以降低死亡或BPD为目的常规启动氢化可的松。
  • 若考虑使用氢化可的松,需权衡其潜在死亡获益与需胰岛素治疗的高血糖风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dexamethasone initiated after the first week of life reduces the rate of death or bronchopulmonary dysplasia (BPD) but may cause long-term adverse effects in very preterm infants. Hydrocortisone is increasingly used as an alternative, but evidence supporting its efficacy and safety is lacking. OBJECTIVE: To assess the effect of hydrocortisone initiated between 7 and 14 days after birth on death or BPD in very preterm infants. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled randomized trial conducted in 19 neonatal intensive care units in the Netherlands and Belgium from November 15, 2011, to December 23, 2016, among preterm infants with a gestational age of less than 30 weeks and/or birth weight of less than 1250 g who were ventilator dependent between 7 and 14 days of life, with follow-up to hospital discharge ending December 12, 2017. INTERVENTIONS: Infants were randomly assigned to receive a 22-day course of systemic hydrocortisone (cumulative dose, 72.5 mg/kg) (n = 182) or placebo (n = 190). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death or BPD assessed at 36 weeks' postmenstrual age. Twenty-nine secondary outcomes were analyzed up to hospital discharge, including death and BPD at 36 weeks' postmenstrual age. RESULTS: Among 372 patients randomized (mean gestational age, 26 weeks; 55% male), 371 completed the trial; parents withdrew consent for 1 child treated with hydrocortisone. Death or BPD occurred in 128 of 181 infants (70.7%) randomized to hydrocortisone and in 140 of 190 infants (73.7%) randomized to placebo (adjusted risk difference, -3.6% [95% CI, -12.7% to 5.4%]; adjusted odds ratio, 0.87 [95% CI, 0.54-1.38]; P = .54). Of 29 secondary outcomes, 8 showed significant differences, including death at 36 weeks' postmenstrual age (15.5% with hydrocortisone vs 23.7% with placebo; risk difference, -8.2% [95% CI, -16.2% to -0.1%]; odds ratio, 0.59 [95% CI, 0.35-0.995]; P = .048). Twenty-one outcomes showed nonsignificant differences, including BPD (55.2% with hydrocortisone vs 50.0% with placebo; risk difference, 5.2% [95% CI, -4.9% to 15.2%]; odds ratio, 1.24 [95% CI, 0.82-1.86]; P = .31). Hyperglycemia requiring insulin therapy was the only adverse effect reported more often in the hydrocortisone group (18.2%) than in the placebo group (7.9%). CONCLUSIONS AND RELEVANCE: Among mechanically ventilated very preterm infants, administration of hydrocortisone between 7 and 14 days after birth, compared with placebo, did not improve the composite outcome of death or BPD at 36 weeks' postmenstrual age. These findings do not support the use of hydrocortisone for this indication. TRIAL REGISTRATION: Netherlands National Trial Register Identifier: NTR2768.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Onland W, Cools F, Kroon A, et al. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA. 2019. PMID: 30694322. doi:10.1001/jama.2018.21443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。